表紙
市場調査レポート

PharmaPoint:全身性エリテマトーデス・ループス腎炎 - フランスにおける医薬品の予測と市場分析

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - France Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 290479
出版日 ページ情報 英文 148 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
PharmaPoint:全身性エリテマトーデス・ループス腎炎 - フランスにおける医薬品の予測と市場分析 PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - France Drug Forecast and Market Analysis to 2022
出版日: 2013年10月31日 ページ情報: 英文 148 Pages
概要

当レポートでは、フランスにおける全身性エリテマトーデス(SLE)・ループス腎炎(LN)治療薬市場について調査分析し、SLE・LNの概要、詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 予後
  • 生活の質(QOL)
  • 症状

第4章 疾患の管理

  • 診断の概要
    • SLEの診断
    • LNの診断
  • 治療の概要
  • フランス
    • 診断
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル - 主要ブランド
    • 抗マラリア性治療
    • ステロイド
    • メトトレキサート
    • ミコフェノール酸モフェチル
    • シクロホスファミド
    • アザチオプリン
    • カルシニューリン阻害剤
    • ベンリスタ(belimumab)
    • リツキサン(rituximab)

第6章 機会とアンメットニーズ

  • 概要
  • アンメットニーズ
    • 副作用を軽減した効果的な治療法
    • LNの管理
    • 患者の死亡率の改善
    • ループス(狼瘡)の併存症の管理
    • 感受性と信頼性の高いバイオマーカー
    • SLEの医師向け教育と啓発活動
    • アンメットニーズのギャップ分析
  • 機会
    • 効果的で安全な治療法
    • LN患者を対象とした治療法
    • ループスの一般的な併存症の治療法
    • バイオマーカーの発見

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤
    • Blisibimod(A-623)
    • Tabalumab(LY-2127399)
    • Atacicept
    • Epratuzumab
    • Lupuzor(rigerimod)
    • Orencia(abatacept)

第8章 市場の見通し

  • フランス
    • 予測
    • 主なイベント
    • 促進要因・障壁

第9章 付録

図表

目次
Product Code: GDHC161CFR

Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.

The growth in the France SLE and LN therapeutics market will be driven by higher uptake of existing biologic drugs and the launch of new biologics and increasing prevalent cases of SLE and LN.

Scope

  • Overview of SLE-LN including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in France from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting France SLE-LN market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for SLE-LN
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in France

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Prognosis
  • 3.3. Quality of Life
  • 3.4. Symptoms

4. Disease Management

  • 4.1. Diagnosis Overview
    • 4.1.1. SLE Diagnosis
    • 4.1.2. LN Diagnosis
  • 4.2. Treatment Overview
  • 4.3. France
    • 4.3.1. Diagnosis
    • 4.3.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Antimalarial Therapy (numerous brand names)
    • 5.3.2. Steroids (numerous brand names)
    • 5.3.3. Methotrexate (numerous brand names)
    • 5.3.4. Mycophenolate Mofetil (numerous brand names)
    • 5.3.5. Cyclophosphamide (numerous brand names)
    • 5.3.6. Azathioprine (numerous brand names)
    • 5.3.7. Calcineurin Inhibitors (numerous brand names)
    • 5.3.8. Benlysta (belimumab)
    • 5.3.9. Rituxan (rituximab)
    • 5.3.10. Minor Therapeutic Classes

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Efficacious Treatments with Reduced Side Effects
    • 6.2.2. Management of LN
    • 6.2.3. Improvement in Patients' Mortality
    • 6.2.4. Management of Lupus Comorbidities
    • 6.2.5. Sensitive and Reliable Biomarkers
    • 6.2.6. Physicians' Education and Public Awareness of SLE
    • 6.2.7. Unmet Needs Gap Analysis
  • 6.3. Opportunities
    • 6.3.1. Efficacious and Safe Therapies
    • 6.3.2. Therapies Targeting LN Patients
    • 6.3.3. Treatments for Common Lupus Comorbidities
    • 6.3.4. Discovery of Biomarkers

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Blisibimod (A-623)
    • 7.2.2. Tabalumab (LY-2127399)
    • 7.2.3. Atacicept
    • 7.2.4. Epratuzumab
    • 7.2.5. Lupuzor (rigerimod)
    • 7.2.6. Orencia (abatacept)

8. Market Outlook

  • 8.1. France
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed SLE and LN Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analysts
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of SLE
  • Table 2: 1997 Updated ACR Criteria for Classification of SLE
  • Table 3: The SLICC Clinical and Immunologic Criteria for Classification of SLE
  • Table 4: WHO and ISN/RPS classifications of LN
  • Table 5: Treatment Guidelines for SLE and LN
  • Table 6: Most Prescribed Drugs for SLE and LN by Class in the Global Markets, 2013
  • Table 7: Leading Treatments for SLE and LN, 2013
  • Table 8: Product Profile - Hydroxychloroquine
  • Table 9: Antimalarial Therapy SWOT Analysis, 2013
  • Table 10: Product Profile - Steroids
  • Table 11: Steroids SWOT Analysis, 2013
  • Table 12: Product Profile - Methotrexate
  • Table 13: Methotrexate SWOT Analysis, 2013
  • Table 14: Product Profile - Mycophenolate Mofetil
  • Table 15: Mycophenolate Mofetil SWOT Analysis, 2013
  • Table 16: Product Profile - Cyclophosphamide
  • Table 17: Cyclophosphamide SWOT Analysis, 2013
  • Table 18: Product Profile - Azathioprine
  • Table 19: Azathioprine SWOT Analysis, 2013
  • Table 20: Product Profile - Calcineurin Inhibitors
  • Table 21: Calcineurin Inhibitors SWOT Analysis, 2013
  • Table 22: Product Profile - Benlysta
  • Table 23: Benlysta SWOT Analysis, 2013
  • Table 24: Product Profile - Rituxan
  • Table 25: Rituxan SWOT Analysis, 2013
  • Table 26: Summary of Minor Therapeutic Classes in SLE and LN, 2013
  • Table 27: Overall Unmet Needs in SLE and LN - Current Level of Attainment
  • Table 28: Clinical Unmet Needs in SLE and LN - Gap Analysis, 2013
  • Table 29: SLE and LN - Phase Pipeline, 2013
  • Table 30: Comparison of Therapeutic Classes in Development for SLE and LN, 2013
  • Table 31: Product Profile - Blisibimod
  • Table 32: Blisibimod SWOT Analysis, 2013
  • Table 33: Product Profile - Tabalumab (LY-2127399)
  • Table 34: Tabalumab SWOT Analysis, 2013
  • Table 35: Product Profile - Atacicept
  • Table 36: Atacicept SWOT Analysis, 2013
  • Table 37: Product Profile - Epratuzumab
  • Table 38: Epratuzumab SWOT Analysis, 2013
  • Table 39: Product Profile - Lupuzor
  • Table 40: Lupuzor SWOT Analysis, 2013
  • Table 41: Product Profile - Orencia
  • Table 42: Orencia SWOT Analysis, 2013
  • Table 43: Sales Forecasts ($m) for SLE in France, 2012-2022
  • Table 44: Sales Forecasts ($m) for LN in France, 2012-2022
  • Table 45: Key Events Impacting Sales for SLE and LN in France, 2012-2022
  • Table 46: SLE and LN Market in France - Drivers and Barriers, 2012-2022
  • Table 47: Key Launch Dates
  • Table 48: Key Patent Expiries
  • Table 49: Number of Physicians Surveyed by Country

List of Figures

  • Figure 1: Overview of the Etiology and Pathogenesis of SLE
  • Figure 2: Overview of the BAFF/APRIL Ligand and Receptor System
  • Figure 3: Overview of the Treatment Management of SLE
  • Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in SLE and LN, 2012-2022
  • Figure 5: Sales for SLE and LN in France by Drug Class, 2012-2022
Back to Top